Verrica Pharmaceuticals Inc.
VRCA
$6.73
-$0.82-10.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.93% | 269.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.93% | 269.35% | |||
| Cost of Revenue | 41.62% | -14.00% | |||
| Gross Profit | 6.45% | 1,343.18% | |||
| SG&A Expenses | 6.22% | 0.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.63% | -3.26% | |||
| Operating Income | 7.75% | 118.57% | |||
| Income Before Tax | -234.31% | 102.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -234.31% | 102.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -234.31% | 102.09% | |||
| EBIT | 7.75% | 118.57% | |||
| EBITDA | 6.24% | 120.45% | |||
| EPS Basic | -234.42% | 102.09% | |||
| Normalized Basic EPS | -234.33% | 102.09% | |||
| EPS Diluted | -244.50% | 101.95% | |||
| Normalized Diluted EPS | -234.33% | 102.09% | |||
| Average Basic Shares Outstanding | 0.02% | 0.05% | |||
| Average Diluted Shares Outstanding | -0.01% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||